Article
Reduced impact of pyrimethamine drug pressure on Plasmodium malariae dihydrofolate reductase gene.
Antimicrobial agents and chemotherapy - 1 Feb 2012
Khim Nimol, Kim Saorin, Bouchier Christiane, Tichit Magali, Ariey Frédéric, Fandeur Thierry, Chim Pheaktra, Ke Sopheakvatey, Sum Sarorn, Man Somnang, Ratsimbasoa Arsène, Durand Rémy, Ménard Didier
Abstract excerpt
Molecular investigations performed following the emergence of sulfadoxine-pyrimethamine (SP) resistance in Plasmodium falciparum have allowed the identification of the dihydrofolate reductase (DHFR) enzyme as the target of pyrimethamine. Although clinical cases of Plasmodium malariae are not usually treated with antifolate therapy, incorrect diagnosis and the high frequency of undetected mixed infections has...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
